Cargando…

Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries

The private for-profit sector is an important source of treatment for malaria. However, private patients face high prices for the recommended treatment for uncomplicated malaria, artemisinin combination therapies (ACTs), which makes them more likely to receive cheaper, less effective non-artemisinin...

Descripción completa

Detalles Bibliográficos
Autores principales: Palafox, Benjamin, Patouillard, Edith, Tougher, Sarah, Goodman, Catherine, Hanson, Kara, Kleinschmidt, Immo, Torres Rueda, Sergio, Kiefer, Sabine, O’Connell, Kate, Zinsou, Cyprien, Phok, Sochea, Akulayi, Louis, Arogundade, Ekundayo, Buyungo, Peter, Mpasela, Felton, Poyer, Stephen, Chavasse, Desmond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748126/
https://www.ncbi.nlm.nih.gov/pubmed/25944705
http://dx.doi.org/10.1093/heapol/czv031
_version_ 1782415069968072704
author Palafox, Benjamin
Patouillard, Edith
Tougher, Sarah
Goodman, Catherine
Hanson, Kara
Kleinschmidt, Immo
Torres Rueda, Sergio
Kiefer, Sabine
O’Connell, Kate
Zinsou, Cyprien
Phok, Sochea
Akulayi, Louis
Arogundade, Ekundayo
Buyungo, Peter
Mpasela, Felton
Poyer, Stephen
Chavasse, Desmond
author_facet Palafox, Benjamin
Patouillard, Edith
Tougher, Sarah
Goodman, Catherine
Hanson, Kara
Kleinschmidt, Immo
Torres Rueda, Sergio
Kiefer, Sabine
O’Connell, Kate
Zinsou, Cyprien
Phok, Sochea
Akulayi, Louis
Arogundade, Ekundayo
Buyungo, Peter
Mpasela, Felton
Poyer, Stephen
Chavasse, Desmond
author_sort Palafox, Benjamin
collection PubMed
description The private for-profit sector is an important source of treatment for malaria. However, private patients face high prices for the recommended treatment for uncomplicated malaria, artemisinin combination therapies (ACTs), which makes them more likely to receive cheaper, less effective non-artemisinin therapies (nATs). This study seeks to better understand consumer antimalarial prices by documenting and exploring the pricing behaviour of retailers and wholesalers. Using data collected in 2009–10, we present survey estimates of antimalarial retail prices, and wholesale- and retail-level price mark-ups from six countries (Benin, Cambodia, the Democratic Republic of Congo, Nigeria, Uganda and Zambia), along with qualitative findings on factors affecting pricing decisions. Retail prices were lowest for nATs, followed by ACTs and artemisinin monotherapies (AMTs). Retailers applied the highest percentage mark-ups on nATs (range: 40% in Nigeria to 100% in Cambodia and Zambia), whereas mark-ups on ACTs (range: 22% in Nigeria to 71% in Zambia) and AMTs (range: 22% in Nigeria to 50% in Uganda) were similar in magnitude, but lower than those applied to nATs. Wholesale mark-ups were generally lower than those at retail level, and were similar across antimalarial categories in most countries. When setting prices wholesalers and retailers commonly considered supplier prices, prevailing market prices, product availability, product characteristics and the costs related to transporting goods, staff salaries and maintaining a property. Price discounts were regularly used to encourage sales and were sometimes used by wholesalers to reward long-term customers. Pricing constraints existed only in Benin where wholesaler and retailer mark-ups are regulated; however, unlicensed drug vendors based in open-air markets did not adhere to the pricing regime. These findings indicate that mark-ups on antimalarials are reasonable. Therefore, improving ACT affordability would be most readily achieved by interventions that reduce commodity prices for retailers, such as ACT subsidies, pooled purchasing mechanisms and cost-effective strategies to increase the distribution coverage area of wholesalers.
format Online
Article
Text
id pubmed-4748126
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-47481262016-02-10 Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries Palafox, Benjamin Patouillard, Edith Tougher, Sarah Goodman, Catherine Hanson, Kara Kleinschmidt, Immo Torres Rueda, Sergio Kiefer, Sabine O’Connell, Kate Zinsou, Cyprien Phok, Sochea Akulayi, Louis Arogundade, Ekundayo Buyungo, Peter Mpasela, Felton Poyer, Stephen Chavasse, Desmond Health Policy Plan Original Articles The private for-profit sector is an important source of treatment for malaria. However, private patients face high prices for the recommended treatment for uncomplicated malaria, artemisinin combination therapies (ACTs), which makes them more likely to receive cheaper, less effective non-artemisinin therapies (nATs). This study seeks to better understand consumer antimalarial prices by documenting and exploring the pricing behaviour of retailers and wholesalers. Using data collected in 2009–10, we present survey estimates of antimalarial retail prices, and wholesale- and retail-level price mark-ups from six countries (Benin, Cambodia, the Democratic Republic of Congo, Nigeria, Uganda and Zambia), along with qualitative findings on factors affecting pricing decisions. Retail prices were lowest for nATs, followed by ACTs and artemisinin monotherapies (AMTs). Retailers applied the highest percentage mark-ups on nATs (range: 40% in Nigeria to 100% in Cambodia and Zambia), whereas mark-ups on ACTs (range: 22% in Nigeria to 71% in Zambia) and AMTs (range: 22% in Nigeria to 50% in Uganda) were similar in magnitude, but lower than those applied to nATs. Wholesale mark-ups were generally lower than those at retail level, and were similar across antimalarial categories in most countries. When setting prices wholesalers and retailers commonly considered supplier prices, prevailing market prices, product availability, product characteristics and the costs related to transporting goods, staff salaries and maintaining a property. Price discounts were regularly used to encourage sales and were sometimes used by wholesalers to reward long-term customers. Pricing constraints existed only in Benin where wholesaler and retailer mark-ups are regulated; however, unlicensed drug vendors based in open-air markets did not adhere to the pricing regime. These findings indicate that mark-ups on antimalarials are reasonable. Therefore, improving ACT affordability would be most readily achieved by interventions that reduce commodity prices for retailers, such as ACT subsidies, pooled purchasing mechanisms and cost-effective strategies to increase the distribution coverage area of wholesalers. Oxford University Press 2016-03 2015-05-05 /pmc/articles/PMC4748126/ /pubmed/25944705 http://dx.doi.org/10.1093/heapol/czv031 Text en © The Author 2015. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Palafox, Benjamin
Patouillard, Edith
Tougher, Sarah
Goodman, Catherine
Hanson, Kara
Kleinschmidt, Immo
Torres Rueda, Sergio
Kiefer, Sabine
O’Connell, Kate
Zinsou, Cyprien
Phok, Sochea
Akulayi, Louis
Arogundade, Ekundayo
Buyungo, Peter
Mpasela, Felton
Poyer, Stephen
Chavasse, Desmond
Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries
title Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries
title_full Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries
title_fullStr Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries
title_full_unstemmed Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries
title_short Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries
title_sort prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748126/
https://www.ncbi.nlm.nih.gov/pubmed/25944705
http://dx.doi.org/10.1093/heapol/czv031
work_keys_str_mv AT palafoxbenjamin pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT patouillardedith pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT toughersarah pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT goodmancatherine pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT hansonkara pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT kleinschmidtimmo pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT torresruedasergio pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT kiefersabine pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT oconnellkate pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT zinsoucyprien pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT phoksochea pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT akulayilouis pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT arogundadeekundayo pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT buyungopeter pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT mpaselafelton pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT poyerstephen pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries
AT chavassedesmond pricesandmarkupsonantimalarialsevidencefromnationallyrepresentativestudiesinsixmalariaendemiccountries